NEUREN PHARMACEUTICALS LIMITED - Announcements

5.76%

$13.10

Market Cap $1.629B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run.

Announcements

Filter Results

All Price Sensitive Only

NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	243.67KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	25/10/12	146KB	Share
NEU	NNZ2566 selected as Windhover Top 10 Neuroscience Project		19/10/12	244.17KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	30/08/12	805.05KB	Share
NEU	Neuren appoints Joe Horrigan VP Clinical and Medical Affairs		09/08/12	178.43KB	Share
NEU	NNZ2566 Rationale in ASDs		07/08/12	1.37MB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/12	232.44KB	Share
NEU	Neuren awarded Rett Syndrome trial grant	PRICE SENSITIVE	06/07/12	220.81KB	Share
NEU	Final Director's Interest Notice		08/06/12	13.58KB	Share
NEU	Initial Director's Interest Notice		08/06/12	12.84KB	Share
NEU	Results of Meeting		31/05/12	60.24KB	Share
NEU	CEO's address to AGM		31/05/12	111.8KB	Share
NEU	Neuren announces cancer xenograft testing results	PRICE SENSITIVE	29/05/12	142.69KB	Share
NEU	Change in substantial holding		25/05/12	100.59KB	Share
NEU	Rett Syndrome pre-IND meeting held with FDA	PRICE SENSITIVE	16/05/12	47.48KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		02/05/12	72.93KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	121.12KB	Share
NEU	Appendix 3B (exercise of options)		27/04/12	68.57KB	Share
NEU	Notice of Annual General Meeting/Proxy Form		27/04/12	214.79KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	19/04/12	118.49KB	Share
NEU	Neuren 2011 Annual Report		30/03/12	1.28MB	Share
NEU	Initial Director's Interest Notice		08/03/12	12.77KB	Share
NEU	Neuren appoints Bruce Hancox to board of directors		08/03/12	37.62KB	Share
NEU	Neuren presentation to Arrowhead TBI Conference		08/03/12	822.65KB	Share
NEU	Neuren 2011 Preliminary Final Report	PRICE SENSITIVE	29/02/12	63.32KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/12	143.59KB	Share
NEU	Neuren to proceed with oral NNZ2566 trial	PRICE SENSITIVE	22/12/11	40.08KB	Share
NEU	Change in substantial holding		12/12/11	65.93KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	09/12/11	145.65KB	Share
NEU	Neuren Completes Phase II trial Cohort 2	PRICE SENSITIVE	21/11/11	43.94KB	Share
NEU	Appendix 3B (exercise of options)		07/11/11	77.76KB	Share
NEU	Change in substantial holding		03/11/11	54.35KB	Share
NEU	Change in substantial holding		03/11/11	53.53KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/11	144.26KB	Share
NEU	Appendix 3B (amendment)		26/10/11	154.76KB	Share
NEU	Change of Director's Interest Notice		26/10/11	28.55KB	Share
NEU	Change of Director's Interest Notice		26/10/11	28.68KB	Share
NEU	Change of Director's Interest Notice		26/10/11	28.61KB	Share
NEU	Change of Director's Interest Notice		26/10/11	28.57KB	Share
NEU	Change of Director's Interest Notice		26/10/11	28.68KB	Share
NEU	Appendix 3B		26/10/11	78.45KB	Share
NEU	Response to ASX Price Query	PRICE SENSITIVE	20/10/11	165.42KB	Share
NEU	Half Yearly Report and Accounts	PRICE SENSITIVE	30/08/11	698.85KB	Share
NEU	Becoming a substantial holder		17/08/11	89.39KB	Share
NEU	Becoming a substantial holder		16/08/11	88.73KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		16/08/11	56.28KB	Share
NEU	Appendix 3B		16/08/11	54.58KB	Share
AEF +NEU	Neuren places $3m of rights issue shortfall	PRICE SENSITIVE	16/08/11	39.13KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/11	91.69KB	Share
NEU	NEU Broker Presentation July 2011		27/07/11	456.38KB	Share
NEU	Neuren CEO presentation to Bioshares Biotech Summit		22/07/11	406.33KB	Share
NEU	Change of Director's Interest Notice		21/07/11	121.53KB	Share
NEU	Change of Director's Interest Notice		21/07/11	16.81KB	Share
NEU	Appendix 3B		19/07/11	54.65KB	Share
NEU	Results of Neuren Rights Issue		19/07/11	53.37KB	Share
NEU	Neuren Confirms Despatch of Rights Issue Offer Documents		29/06/11	1.44MB	Share
NEU	Appendix 3B		28/06/11	53.2KB	Share
NEU	CEO presentation to AusBiotech New York		24/06/11	300.93KB	Share
NEU	Rights Issue Eligible Shareholder Notice		20/06/11	69.86KB	Share
NEU	Change in substantial holding		20/06/11	172.47KB	Share
NEU	Rights Issue Notice to Foreign Shareholders		15/06/11	58.17KB	Share
NEU	Rights Issue Notice to Optionholders		15/06/11	72.25KB	Share
NEU	Rights Issue Notice under Section 708AA		15/06/11	58.35KB	Share
NEU	Appendix 3B (renounceable rights issue)		15/06/11	55.66KB	Share
NEU	Neuren Rights Issue Letter of Offer (Australian residents)	PRICE SENSITIVE	15/06/11	765.09KB	Share
NEU	Neuren Rights Issue Offer Document (NZ residents)	PRICE SENSITIVE	15/06/11	793.18KB	Share
NEU	Neuren announces Renounceable Rights Issue	PRICE SENSITIVE	15/06/11	22.64KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		06/06/11	56.35KB	Share
NEU	Neuren completes placement and converts remaining note		06/06/11	20.22KB	Share
NEU	Appendix 3B (options)		06/06/11	53.27KB	Share
NEU	Appendix 3B (shares)		06/06/11	52.57KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		03/06/11	56.37KB	Share
NEU	Appendix 3B		03/06/11	52.95KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		02/06/11	56.49KB	Share
NEU	Appendix 3B		02/06/11	52.84KB	Share
NEU	Results of Annual Meeting		31/05/11	45.74KB	Share
NEU	Results of Special Meeting		31/05/11	45.22KB	Share
NEU	Neuren CEO Presentation to AGM		31/05/11	596.63KB	Share
NEU	Neuren reduces outstanding convertible note principal	PRICE SENSITIVE	20/05/11	23.25KB	Share
NEU	Neuren's Perseis selects lead antibodies	PRICE SENSITIVE	19/05/11	713.58KB	Share
NEU	Notice of Special Shareholders Meeting/Proxy Form		13/05/11	144.01KB	Share
NEU	Neuren Completes Phase II trial Cohort 1	PRICE SENSITIVE	11/05/11	26.32KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		06/05/11	57.65KB	Share
NEU	Appendix 3B		06/05/11	54.2KB	Share
NEU	Becoming a substantial holder		05/05/11	167.64KB	Share
NEU	Neuren Announces Private Placement and Rights Issue	PRICE SENSITIVE	04/05/11	25.82KB	Share
NEU	Trading Halt	PRICE SENSITIVE	02/05/11	95.34KB	Share
NEU	Notice of Annual General Meeting/Proxy Form		29/04/11	178.8KB	Share
NEU	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/11	93.43KB	Share
NEU	Appendix 3B		27/04/11	61.73KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		20/04/11	59.86KB	Share
NEU	Appendix 3B		20/04/11	54.04KB	Share
NEU	Appendix 3B		20/04/11	54.42KB	Share
NEU	Annual Report to shareholders		31/03/11	538.46KB	Share
NEU	Appendix 3B		23/03/11	61.54KB	Share
NEU	Notice under section 708A(5)(e) of the Corporations Act		22/03/11	60.02KB	Share
NEU	Appendix 3B		21/03/11	54.5KB	Share
NEU	Appendix 3B		21/03/11	54.1KB	Share
NEU	Appendix 3B		21/03/11	54.61KB	Share
NEU	Results of Meeting		21/03/11	44.49KB	Share

NEUAppendix 4C - quarterly
31/10/12	PRICE SENSITIVE	243.67KB	Share
NEUResponse to ASX Price Query
25/10/12	PRICE SENSITIVE	146KB	Share
NEUNNZ2566 selected as Windhover Top 10 Neuroscience Project
19/10/12		244.17KB	Share
NEUHalf Yearly Report and Accounts
30/08/12	PRICE SENSITIVE	805.05KB	Share
NEUNeuren appoints Joe Horrigan VP Clinical and Medical Affairs
09/08/12		178.43KB	Share
NEUNNZ2566 Rationale in ASDs
07/08/12		1.37MB	Share
NEUAppendix 4C - quarterly
31/07/12	PRICE SENSITIVE	232.44KB	Share
NEUNeuren awarded Rett Syndrome trial grant
06/07/12	PRICE SENSITIVE	220.81KB	Share
NEUFinal Director's Interest Notice
08/06/12		13.58KB	Share
NEUInitial Director's Interest Notice
08/06/12		12.84KB	Share
NEUResults of Meeting
31/05/12		60.24KB	Share
NEUCEO's address to AGM
31/05/12		111.8KB	Share
NEUNeuren announces cancer xenograft testing results
29/05/12	PRICE SENSITIVE	142.69KB	Share
NEUChange in substantial holding
25/05/12		100.59KB	Share
NEURett Syndrome pre-IND meeting held with FDA
16/05/12	PRICE SENSITIVE	47.48KB	Share
NEUNotice under section 708A(5)(e) of the Corporations Act
02/05/12		72.93KB	Share
NEUAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	121.12KB	Share
NEUAppendix 3B (exercise of options)
27/04/12		68.57KB	Share
NEUNotice of Annual General Meeting/Proxy Form
27/04/12		214.79KB	Share
NEUResponse to ASX Price Query
19/04/12	PRICE SENSITIVE	118.49KB	Share
NEUNeuren 2011 Annual Report
30/03/12		1.28MB	Share
NEUInitial Director's Interest Notice
08/03/12		12.77KB	Share
NEUNeuren appoints Bruce Hancox to board of directors
08/03/12		37.62KB	Share
NEUNeuren presentation to Arrowhead TBI Conference
08/03/12		822.65KB	Share
NEUNeuren 2011 Preliminary Final Report
29/02/12	PRICE SENSITIVE	63.32KB	Share
NEUAppendix 4C - quarterly
31/01/12	PRICE SENSITIVE	143.59KB	Share
NEUNeuren to proceed with oral NNZ2566 trial
22/12/11	PRICE SENSITIVE	40.08KB	Share
NEUChange in substantial holding
12/12/11		65.93KB	Share
NEUResponse to ASX Price Query
09/12/11	PRICE SENSITIVE	145.65KB	Share
NEUNeuren Completes Phase II trial Cohort 2
21/11/11	PRICE SENSITIVE	43.94KB	Share
NEUAppendix 3B (exercise of options)
07/11/11		77.76KB	Share
NEUChange in substantial holding
03/11/11		54.35KB	Share
NEUChange in substantial holding
03/11/11		53.53KB	Share
NEUAppendix 4C - quarterly
28/10/11	PRICE SENSITIVE	144.26KB	Share
NEUAppendix 3B (amendment)
26/10/11		154.76KB	Share
NEUChange of Director's Interest Notice
26/10/11		28.55KB	Share
NEUChange of Director's Interest Notice
26/10/11		28.68KB	Share
NEUChange of Director's Interest Notice
26/10/11		28.61KB	Share
NEUChange of Director's Interest Notice
26/10/11		28.57KB	Share
NEUChange of Director's Interest Notice
26/10/11		28.68KB	Share
NEUAppendix 3B
26/10/11		78.45KB	Share
NEUResponse to ASX Price Query
20/10/11	PRICE SENSITIVE	165.42KB	Share
NEUHalf Yearly Report and Accounts
30/08/11	PRICE SENSITIVE	698.85KB	Share
NEUBecoming a substantial holder
17/08/11		89.39KB	Share
NEUBecoming a substantial holder
16/08/11		88.73KB	Share
NEUNotice under section 708A(5)(e) of the Corporations Act
16/08/11		56.28KB	Share
NEUAppendix 3B
16/08/11		54.58KB	Share
AEF +NEUNeuren places $3m of rights issue shortfall
16/08/11	PRICE SENSITIVE	39.13KB	Share
NEUAppendix 4C - quarterly
29/07/11	PRICE SENSITIVE	91.69KB	Share
NEUNEU Broker Presentation July 2011
27/07/11		456.38KB	Share
NEUNeuren CEO presentation to Bioshares Biotech Summit
22/07/11		406.33KB	Share
NEUChange of Director's Interest Notice
21/07/11		121.53KB	Share
NEUChange of Director's Interest Notice
21/07/11		16.81KB	Share
NEUAppendix 3B
19/07/11		54.65KB	Share
NEUResults of Neuren Rights Issue
19/07/11		53.37KB	Share
NEUNeuren Confirms Despatch of Rights Issue Offer Documents
29/06/11		1.44MB	Share
NEUAppendix 3B
28/06/11		53.2KB	Share
NEUCEO presentation to AusBiotech New York
24/06/11		300.93KB	Share
NEURights Issue Eligible Shareholder Notice
20/06/11		69.86KB	Share
NEUChange in substantial holding
20/06/11		172.47KB	Share
NEURights Issue Notice to Foreign Shareholders
15/06/11		58.17KB	Share
NEURights Issue Notice to Optionholders
15/06/11		72.25KB	Share
NEURights Issue Notice under Section 708AA
15/06/11		58.35KB	Share
NEUAppendix 3B (renounceable rights issue)
15/06/11		55.66KB	Share
NEUNeuren Rights Issue Letter of Offer (Australian residents)
15/06/11	PRICE SENSITIVE	765.09KB	Share
NEUNeuren Rights Issue Offer Document (NZ residents)
15/06/11	PRICE SENSITIVE	793.18KB	Share
NEUNeuren announces Renounceable Rights Issue
15/06/11	PRICE SENSITIVE	22.64KB	Share
NEUNotice under section 708A(5)(e) of the Corporations Act
06/06/11		56.35KB	Share
NEUNeuren completes placement and converts remaining note
06/06/11		20.22KB	Share
NEUAppendix 3B (options)
06/06/11		53.27KB	Share
NEUAppendix 3B (shares)
06/06/11		52.57KB	Share
NEUNotice under section 708A(5)(e) of the Corporations Act
03/06/11		56.37KB	Share
NEUAppendix 3B
03/06/11		52.95KB	Share
NEUNotice under section 708A(5)(e) of the Corporations Act
02/06/11		56.49KB	Share
NEUAppendix 3B
02/06/11		52.84KB	Share
NEUResults of Annual Meeting
31/05/11		45.74KB	Share
NEUResults of Special Meeting
31/05/11		45.22KB	Share
NEUNeuren CEO Presentation to AGM
31/05/11		596.63KB	Share
NEUNeuren reduces outstanding convertible note principal
20/05/11	PRICE SENSITIVE	23.25KB	Share
NEUNeuren's Perseis selects lead antibodies
19/05/11	PRICE SENSITIVE	713.58KB	Share
NEUNotice of Special Shareholders Meeting/Proxy Form
13/05/11		144.01KB	Share
NEUNeuren Completes Phase II trial Cohort 1
11/05/11	PRICE SENSITIVE	26.32KB	Share
NEUNotice under section 708A(5)(e) of the Corporations Act
06/05/11		57.65KB	Share
NEUAppendix 3B
06/05/11		54.2KB	Share
NEUBecoming a substantial holder
05/05/11		167.64KB	Share
NEUNeuren Announces Private Placement and Rights Issue
04/05/11	PRICE SENSITIVE	25.82KB	Share
NEUTrading Halt
02/05/11	PRICE SENSITIVE	95.34KB	Share
NEUNotice of Annual General Meeting/Proxy Form
29/04/11		178.8KB	Share
NEUAppendix 4C - quarterly
29/04/11	PRICE SENSITIVE	93.43KB	Share
NEUAppendix 3B
27/04/11		61.73KB	Share
NEUNotice under section 708A(5)(e) of the Corporations Act
20/04/11		59.86KB	Share
NEUAppendix 3B
20/04/11		54.04KB	Share
NEUAppendix 3B
20/04/11		54.42KB	Share
NEUAnnual Report to shareholders
31/03/11		538.46KB	Share
NEUAppendix 3B
23/03/11		61.54KB	Share
NEUNotice under section 708A(5)(e) of the Corporations Act
22/03/11		60.02KB	Share
NEUAppendix 3B
21/03/11		54.5KB	Share
NEUAppendix 3B
21/03/11		54.1KB	Share
NEUAppendix 3B
21/03/11		54.61KB	Share
NEUResults of Meeting
21/03/11		44.49KB	Share

REFRESH

First 5 6 7 8 9

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.10		Change -0.800(5.76%)		Mkt cap ! $1.629B

Open	High	Low	Value	Volume
$13.95	$13.96	$12.88	$9.534M	725.6K

Buyers (Bids)

No.	Vol.	Price($)
1	266	$13.10

Sellers (Offers)

Price($)	Vol.	No.
$13.15	1619	2

View Market Depth

No.	Vol.	Price($)
1	667	13.080
2	154	13.000
1	77	12.930
1	39	12.920
1	21	12.900

Price($)	Vol.	No.
13.190	1305	1
13.560	2250	1
13.880	748	1
14.000	60	1
14.020	10000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories